Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice

Vartiainen, Ville and Raula, Janne and Bimbo, Luis M. and Viinamäki, Jenni and T. Backman, Janne and Ugur, Nurcin and Kauppinen, Esko and Sutinen, Eva and Joensuu, Emmi and Koli, Katri and Myllärniemi, Marjukka (2018) Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. International Journal of Pharmaceutics, 544 (1). pp. 121-128. ISSN 0378-5173

[img]
Preview
Text (Vartiainen-etal-IJP-2018-Pulmonary-administration-of-a-dry-powder-formulation-of-the-antifibrotic-drug-tilorone)
Vartiainen_etal_IJP_2018_Pulmonary_administration_of_a_dry_powder_formulation_of_the_antifibrotic_drug_tilorone.pdf
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (1MB)| Preview

    Abstract

    The aim of this work was to study the antifibrotic effect of pulmonary administration of tilorone to lung fibrosis. L-leucine coated tilorone particles were prepared and their aerosolization properties were analyzed using two dry powder inhalers (Easyhaler and Twister). In addition, the biological activity and cell monolayer permeation was tested. The antifibrotic effect of tilorone delivered by oropharyngeal aspiration was studied in vivo using a silica-induced model of pulmonary fibrosis in mice in a preventive setting. When delivered from the Easyhaler in an inhalation simulator, the emitted dose and fine particle fraction were independent from the pressure applied and showed dose repeatability. However, with Twister the aerosolization was pressure-dependent indicating poor compatibility between the device and the formulation. The formulation showed more consistent permeation through a differentiated Calu-3 cell monolayer compared to pristine tilorone. Tilorone decreased the histological fibrosis score in vivo in systemic and local administration, but only systemic administration decreased the mRNA expression of type I collagen. The difference was hypothesized to result from 40-fold higher drug concentration in tissue samples in the systemic administration group. These results show that tilorone can be formulated as inhalable dry powder and has potential as an oral and inhalable antifibrotic drug